Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab plus supportive therapy versus supportive therapy in early non-nephrotic primary membranous nephropathy
ChiCTR2000033540Phase 4Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Jun 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of rituximab in membranous glomerulonephritis (MGN) and idiopathic membranous glomerulonephritis (IMG) (2 arms), sponsored by Peking Union Medical College Hospital. Primary endpoints: 24-hour urine protein, Serum albumin and 3 more. Started Jun 2020; status: recruiting.
02
Drugs
rituximab
03
Conditions
membranous glomerulonephritis (MGN)idiopathic membranous glomerulonephritis (IMG)
Beyond the preview
Go deeper on ChiCTR2000033540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000033540.